Skip to main content
. Author manuscript; available in PMC: 2011 Feb 1.
Published in final edited form as: Am J Geriatr Psychiatry. 2010 Feb;18(2):136–145. doi: 10.1097/JGP.0b013e3181c796eb

Table 1.

Demographics and clinical variables at baseline

Total Sertraline Placebo
No. randomized 131 67 64
Age, mean (sd), years 77.3 (8.0) 76.5 (8.0) 78.2 (8.0)
Gender, %
  Female 54.2 59.7 48.4
  Male 45.8 40.3 51.6
Ethnic Group, %
  White, non-Hispanic 67.2 73.1 60.9
  African-American 21.4 17.9 25.0
  Hispanic / Latino 10.7   7.5 14.1
  Asian   0.8   1.5   0
Marital status, %
  Married 64.1 64.2 64.1
  Widowed 25.2 26.9 23.4
  Divorced / separated   6.1   4.5   7.8
  Never married   4.6   4.5   4.7
Education, mean (sd), years 12.5 (3.7) 13.2 (3.6) 11.8 (3.8)
Duration of dementia, mean (sd), years   2.8 (2.2)   2.6 (2.1)   3.1 (2.3)
Depression episodes before cognitive symptoms, %
  No episodes 74.0 77.6 70.3
  One episode 16.8 13.4 20.3
  Two or more episodes   7.6   6.0   9.4
  Missing   1.5   3.0   0
Depression episodes since cognitive symptoms, %
  One episode 86.3 86.6 85.9
  Two or more episodes 12.9 12.0 14.1
  Missing   0.8   1.5   0
History of mood disorder in first degree relative, % 16.0 13.4 18.8
Personal history of mood disorder, % 27.5 25.4 29.7
Cornell Scale for Depression in Dementia, median, (1st
quartile, 3rd quartile)
13 (9, 18) 13 (9,19) 13 (9.5, 17)
Mini-mental State Examination, mean (sd) 20.0 (4.6) 20.6 (4.5) 19.3 (4.8)
Taking only cholinesterase inhibitors (%) 38 40 36
Taking only memantine (%)   6.1   6.0   6.3
Taking both memantine and cholinesterase inhibitors (%) 26 25 26
Diagnosis of Major Depressive Episode (MDE), % 39.7 38.8 40.6